文献速递肝病

沙罗格列扎(双重PPARα/γ激动剂)改善非肝硬化非酒精性脂肪性肝病患者的致动脉粥样硬化性血脂异常:汇总分析

Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-01-31

该汇总分析纳入2项双盲安慰剂对照随机临床试验的221例非酒精性脂肪性肝病患者(沙罗格列扎130例,安慰剂91例),评估沙罗格列扎镁4 mg对血脂的影响。结果显示沙罗格列扎显著改善总胆固醇、甘油三酯、低密度脂蛋白胆固醇、极低密度脂蛋白胆固醇及小而密低密度脂蛋白胆固醇,且不依赖糖尿病、高血压及他汀使用情况。

要点

  • 沙罗格列扎镁4 mg显著降低NAFLD患者总胆固醇、甘油三酯、LDL-C、VLDL-C及sdLDL-C。
  • 血脂改善在治疗开始后4-6周即出现,并持续于整个治疗期间。
  • 在糖尿病或高血压亚组中,沙罗格列扎同样显著改善血脂。

核心结论

  • 沙罗格列扎改善NAFLD患者的血清致动脉粥样硬化性脂蛋白谱,不受合并症及他汀使用影响。
  • 沙罗格列扎可能不仅对肝脏疾病有正面影响,还可降低NAFLD患者的心血管风险。

研究设计与样本

  • 汇总2项2期和3期双盲安慰剂对照随机临床试验,共221例NAFLD患者(沙罗格列扎130例,安慰剂91例)。
  • 评估沙罗格列扎镁4 mg对传统血脂、VLDL-C及sdLDL-C的影响,采用协方差分析,以治疗为固定效应,基线值、糖尿病、高血压及他汀使用为协变量。

主要发现

  • 总胆固醇降低17 mg/dL(95%CI -24至9,P < .001)。
  • 甘油三酯降低45 mg/dL(95%CI -60至31,P < .001)。
  • LDL-C降低8 mg/dL(95%CI -15至-1,P = .01)。
  • VLDL-C降低8 mg/dL(95%CI -14至-3,P < .001)。
  • sdLDL-C降低10 mg/dL(95%CI -17至-2,P = .01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Cardiovascular disease is the leading cause of mortality in nonalcoholic fatty liver disease (NAFLD). The aim of this study was to evaluate the effects of saroglitazar, a dual peroxisome proliferator-activated receptor α/γ agonist, on serum lipids in patients with NAFLD. METHODS: A total of 221 patients (saroglitazar, 130; placebo, 91) with NAFLD from phase 2 and 3 double-blinded placebo-controlled randomized clinical trials were pooled to assess the impact of saroglitazar magnesium 4 mg on traditional lipids, very low density lipoprotein cholesterol (VLDL-C), and small dense LDL-C (sdLDL-C). Change from baseline in lipid parameters was performed by using analysis of covariance including treatment as fixed effect and baseline value, diabetes, hypertension, and statin use as covariates. RESULTS: Treatment with saroglitazar significantly improved total cholesterol (-17 mg/dL, 95% confidence interval [CI], -24 to 9; P < .001), triglyceride (-45 mg/dL, 95% CI, -60 to 31; P < .001), low-density lipoprotein cholesterol (-8 mg/dL, 95% CI, -15 to -1; P = .01), and VLDL-C (-8 mg/dL, -14 to -3; P < .001). Saroglitazar improved serum lipids as early as 4-6 weeks of initiation of therapy, and these effects persisted for duration of therapy. Saroglitazar also improved the highly atherogenic sdLDL-C (-10 mg/dL, -17 to -2; P = .01). In subgroup analysis of patients with either diabetes or hypertension, saroglitazar significantly improved serum lipids. CONCLUSIONS: Saroglitazar improved the serum atherogenic lipoprotein profile in patients with NAFLD, irrespective of comorbid conditions and statin use. Saroglitazar has the potential to not only positively affect liver disease but also reduce cardiovascular risk in patients with NAFLD. (Trials registrations: CTRI 2015/10/006236, CTRI 173300410A0106, NCT03863574, and NCT03061721).

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Siddiqui MS, Parmar D, Sheikh F, et al. Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis. Clin Gastroenterol Hepatol. 2023. PMID: 36731585. doi:10.1016/j.cgh.2023.01.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。